Mutations that constitutively activate RET are always detected in familial forms of MTC and Multiple Endocrine Neoplasia (MEN) 2A and the proliferation of MEN2 patient-derived MTC cell lines is inhibited by Vandetanib [19]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.